Google Cloud Symposium on Regulatory Compliance & AI, Field Notes & Analysis

Audience: senior quality, regulatory, security & engineering leaders across MedTech, BioPharma, and Health IT
Venue: Google Office, New York City

Executive Summary

The life sciences sector is in a decisive transition. The last technology cycle moved regulated workloads from on‑premises data centers to hyperscale cloud; the next cycle fuses cloud with AI under tightening, better‑defined regulatory expectations. This symposium at Google’s NYC office focused on practical tooling and patterns emerging on Google Cloud and on the policy shifts shaping compliant adoption across Pharma, MedTech, and BioPharma.

Core themes

1. Cloud + AI are finally colliding with GxP and SaMD. Policy frameworks such as TEFCA, CSA, GMLP, and NIH’s alignment to NIST 800-171 are maturing at the same time that vendors are releasing practical tooling for continuous, evidence-based compliance. The result is a shift away from static, point-in-time validation and toward systems that are instrumented, observable, and continually assessed as part of normal operations.

2. Expect fewer prescriptive rules but more audits and inquiries. As interoperability expands and data sharing becomes easier, privacy barriers soften and visibility increases. A single inquiry from an agency, while not inherently harmful, can surface misinformation, inconsistencies, or misaligned narratives if an organization does not maintain traceability, semantic coherence, and rapid, well-supported response workflows. The operating model must assume scrutiny, not as an exception but as a steady-state condition.

Keynote by Vid Desai (Former CIO, FDA)

Vid opened with a stark comparison: the United States spends dramatically more per capita on healthcare than peer nations, yet consistently underperforms on life expectancy and other key outcomes[1] [2] [3].

He emphasized that the regulatory system was initially designed to support stringent, resource-intensive oversight of blockbuster therapies. Today, however, manufacturers increasingly depend on portfolios of 8 or 9 specialty therapies rather than a single mass-market product. That shift strains an approval pipeline not designed for high-mix, small-population treatments and highlights the need for new tools, policies, and regulatory mechanisms.

The primary bottlenecks he described include:

• Regulatory throughput: Priority review vouchers and accelerated pathways help, but they function more as stopgaps than systemic solutions. The PRV programs and the newer CNPV pilot attempt to speed reviews aligned to national priorities, but the underlying capacity challenges remain [4] [5].

• Policy shift: Alongside the interoperability momentum from the 21st Century Cures Act and TEFCA, the White House’s 10-out/1-in policy (E.O. 14192) reflects a broader deregulatory posture. This environment favors fewer prescriptive rules, more inquiries, and greater transparency expectations[6] [7].

“Treatments are more specialized; you now need eight to nine niche therapies to match one blockbuster’s revenue.”
(context from session)

Vid underscored that innovation is essential. While the 10-out/1-in policy may not be the long-term regulatory solution, it reflects a growing willingness to revisit and in some cases retire outdated rules rather than layering new ones on top without justification.

He also addressed the concept of a “health passport” and the broader challenge around patient-owned data. Much of a patient’s clinical history exists in digitized form across government or clinical systems, yet individuals lack a unified, accessible, consumer-grade interface to view, control, or share it.

Areas of exploration included:

• Patient opt-in portals: intuitive UX that allows patients to voluntarily share outcomes, symptoms, and device events.
• The role of TEFCA and FHIR as the foundational infrastructure enabling secure data exchange, while privacy controls such as explicit opt-ins, revocation, and transparency logs maintain trust[8].

Overall, Vid’s comments underscored how far the healthcare ecosystem still has to go in aligning regulatory expectations with modern innovation. One closing point that extended beyond the idea of a national health passport involved the persistent inability of patients to meaningfully price-shop for medical services. Even basic comparison tools, something Google has delivered across retail, travel, and consumer markets for years, have been largely absent in U.S. healthcare.

With the passage and enforcement of federal hospital price-transparency rules, including the Hospital Price Transparency Final Rule and the No Surprises Act, there is finally infrastructure compelling providers to publish machine-readable, consumer-accessible pricing data. This regulatory shift may open the door to the type of comparison engines, aggregators, and “Google Shopping-style” experiences that have long existed in every other sector [9].

Session — Brandi Stockton: GAMP in the Age of AI

Challenges

• Embedding AI into GxP processes such as risk management, drift detection, supplier assessment, and data provenance.
• Distinguishing static systems from dynamic, continuously learning systems, and defining controls to manage model drift and intended use.

Current frameworks to rely on

• GAMP 5, Second Edition, which centers on critical thinking, clearer supplier roles, modern SDLC expectations, and practical automation approaches [10] [11].
• The ISPE GAMP AI Guide (2025), which introduces governance patterns for AI in GxP environments, including risk taxonomies, lifecycle controls, and data management requirements [12] [13] [14].
• FDA’s Computer Software Assurance (CSA) framework, which supports risk-based testing and flexible validation strategies for both traditional and AI-enabled systems.

After the morning sessions, we moved into an afternoon of technical demonstrations and feedback discussions.

Demo — Regulatory Agents, Kamiya Sargoch

Kamiya showed how pieces of the GCP stack can support regulatory teams, including the ability to scan a premarket submission and automatically flag inconsistencies against standards. The goal is early detection of errors, not replacing reviewers.

The agent patterns focus on semantic coherence, addressing contradictions between narratives and source tables, and coordinating follow-up actions such as tagging owners or drafting RTQ responses. This is powered by retrieval over FDA/ICH guidance and the ability to generate FHIR-aligned outputs [9].

She emphasized these are patterns, not products, built on Vertex and Gemini with strict isolation and required human review.

Product — Google Cloud Compliance Manager, Michelle Jin

Michelle delivered a concise walkthrough of Compliance Manager, showing how teams can apply frameworks, monitor violations, and generate audit artifacts directly in GCP. She previewed upcoming capabilities, and we also discussed nuances in compliance management, such as future traceability matrices, impact forecasting, and in-console agentic assistants. Full documentation of current functionality is here: [15]. Michelle’s talk also covered GxP-specific considerations, Part 11 expectations, validation scope, and NIH-aligned NIST 800-171 requirements, which remain active constraints for regulated cloud deployments [16].

Remarks from Bill Reid (Google)

Bill’s afternoon session focused on the future of data use, transparency, and cross-ecosystem interoperability, building on Vid’s themes around systemic bottlenecks. He emphasized that even lightweight threat-modeling approaches such as STRIDE offer meaningful structure for startups and small teams [17]. Bill also noted that synthetic or simulated datasets can accelerate development when real data are scarce—provided teams clearly document representativeness and limitations. Finally, he pointed to TEFCA and FHIR as enablers of true cross-network exchange and patient-directed access, suggesting that earlier attempts like Microsoft HealthVault struggled due to misaligned incentives and immature infrastructure, conditions that have now materially shifted[8] [18].

Closing Remarks

These notes serve both as a personal glossary and a grounding reference for ideas worth carrying forward. Beyond the clear signals about where future products and systems are headed, the sessions underscored the significant opportunity for companies like GCP and the broader Google ecosystem to work more closely with builders such as GKS. Aligning product capabilities with real customer workflows will be essential, and events like this make it clear that collaboration between platform teams and domain-focused innovators is no longer optional but the path to meaningful progress.

Author

This blog was written by George Kwiecinski. The views expressed here reflect his own analysis and perspective. For questions or inquiries, please contact: [email protected]